Social Anxiety Disorder Study Of Paroxetine

Study Overview
=================
Brief Summary
-----------------
This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD).

Official Title
-----------------
Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Double-blind, Placebo-controlled Study- <Phase III Study>

Conditions
-----------------
Social Phobia

Intervention / Treatment
-----------------
* Drug: Paroxetine hydrochloride hydrate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Diagnosis of Social Anxiety Disorder (SAD) (300.23 Social Phobia/Social Anxiety Disorder) according to DSM-IV-TR criteria. Must give a written informed consent. But if the patient is under 20, both the patient himself/herself and his/her proxy consenter must give written informed consent. Patients have a minimum score of 60 on the LSAS total score. Exclusion criteria: Patients primarily diagnosed with a disorder that is categorized into Axis I excluding SAD by DSM-IV-TR (e.g. major depression, dysthymic disorder, specific phobia (simple phobia) , obsessive compulsive disorder, panic disorder) within 24weeks before week -2. Patients with a history or complication of schizophrenia and bipolar disorder Patients with a complication of body dysmorphic disorder. Patients with evidence of substance abuse (alcohol or drugs) substance dependence by DSM-IV-TR criteria within 24 weeks before week -2. Patients who started psychotherapy and cognitive-behavioural therapy within 24 weeks before week-2, except for supportive psychotherapy. Patients receiving electro-convulsive therapy (ECT) within 12 weeks before week -2. Patients being pregnant, lactating or are of childbearing potential and are likely to become pregnant. Patients with 3 or more points of HAM-D Item No. 3, or who are likely to attempt suicide. Patients with a history or complication of cancer or malignant tumor. Patients receiving MAO inhibitors (FP®) within 14 days before expected week 0 visit date.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Paroxetine hydrochloride hydrate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in the LSAS total score at week 12 (Score at week 12 - Score at week 0) |  | 12 Weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients responding with a CGI Global Improvement Item score. Change from baseline in the CGI Severity of Illness score. Change from baseline in the HAM-D total score. Proportion of patients continuing treatment. |  | 12 Weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anxiety, SAD, Social, Disorder